UniSC begins clinical trial of potential world-first human vaccine to prevent chlamydia

UniSC Clinical Trials has begun investigating a potential world-first human chlamydia vaccine to protect against infection and reinfection.

Overall, 1,500 young Australian adults who are sexually active will be recruited to join the study, with the vaccine to be administered at trial sites nationwide.

The first 120 participants will begin receiving the investigational vaccine at UniSC Clinical Trial centres at Southbank, Morayfield and the Sunshine Coast.